These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33776771)

  • 1. Pharmacological Insights Into Safety and Efficacy Determinants for the Development of Adenosine Receptor Biased Agonists in the Treatment of Heart Failure.
    Rueda P; Merlin J; Chimenti S; Feletou M; Paysant J; White PJ; Christopoulos A; Sexton PM; Summers RJ; Charman WN; May LT; Langmead CJ
    Front Pharmacol; 2021; 12():628060. PubMed ID: 33776771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capadenoson, a clinically trialed partial adenosine A
    Baltos JA; Vecchio EA; Harris MA; Qin CX; Ritchie RH; Christopoulos A; White PJ; May LT
    Biochem Pharmacol; 2017 Jul; 135():79-89. PubMed ID: 28344125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial Adenosine A1 Agonist in Heart Failure.
    Dinh W; Albrecht-Küpper B; Gheorghiade M; Voors AA; van der Laan M; Sabbah HN
    Handb Exp Pharmacol; 2017; 243():177-203. PubMed ID: 27770217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery.
    Baltos JA; Gregory KJ; White PJ; Sexton PM; Christopoulos A; May LT
    Biochem Pharmacol; 2016 Jan; 99():101-12. PubMed ID: 26581123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the Role of the Linker in Bitopic
    Awalt JK; Nguyen ATN; Fyfe TJ; Thai BS; White PJ; Christopoulos A; Jörg M; May LT; Scammells PJ
    J Med Chem; 2022 Jul; 65(13):9076-9095. PubMed ID: 35729775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure.
    Voors AA; Düngen HD; Senni M; Nodari S; Agostoni P; Ponikowski P; Bax JJ; Butler J; Kim RJ; Dorhout B; Dinh W; Gheorghiade M
    J Clin Pharmacol; 2017 Apr; 57(4):440-451. PubMed ID: 27624622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A
    Meibom D; Albrecht-Küpper B; Diedrichs N; Hübsch W; Kast R; Krämer T; Krenz U; Lerchen HG; Mittendorf J; Nell PG; Süssmeier F; Vakalopoulos A; Zimmermann K
    ChemMedChem; 2017 May; 12(10):728-737. PubMed ID: 28488817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.
    Voors AA; Bax JJ; Hernandez AF; Wirtz AB; Pap AF; Ferreira AC; Senni M; van der Laan M; Butler J;
    Eur J Heart Fail; 2019 Nov; 21(11):1426-1433. PubMed ID: 31523892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of two selective A
    Cooper SL; March J; Sabbatini AR; Hill SJ; Jörg M; Scammells PJ; Woolard J
    Br J Pharmacol; 2020 Jan; 177(2):346-359. PubMed ID: 31596949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction.
    Voors AA; Shah SJ; Bax JJ; Butler J; Gheorghiade M; Hernandez AF; Kitzman DW; McMurray JJV; Wirtz AB; Lanius V; van der Laan M; Solomon SD
    Eur J Heart Fail; 2018 Nov; 20(11):1601-1610. PubMed ID: 30225882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model.
    Chuo CH; Devine SM; Scammells PJ; Krum H; Christopoulos A; May LT; White PJ; Wang BH
    Clin Exp Pharmacol Physiol; 2016 Oct; 43(10):976-82. PubMed ID: 27377874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of cAMP-PKA pathway in adenosine A1 and A2A receptor-mediated regulation of acetaldehyde-induced activation of HSCs.
    Yang Y; Wang H; Lv X; Wang Q; Zhao H; Yang F; Yang Y; Li J
    Biochimie; 2015 Aug; 115():59-70. PubMed ID: 25956975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The different effects of four adenosine receptors in liver fibrosis.
    Yang L; Gao ZW; Wang X; Wu XN; Li SM; Dong K; Zhu XM
    Front Pharmacol; 2024; 15():1424624. PubMed ID: 39290867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of efficacy of a partial adenosine A1 receptor agonist in neuropathic pain models in mice.
    Metzner K; Gross T; Balzulat A; Wack G; Lu R; Schmidtko A
    Purinergic Signal; 2021 Sep; 17(3):503-514. PubMed ID: 34313915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.
    Vecchio EA; Chuo CH; Baltos JA; Ford L; Scammells PJ; Wang BH; Christopoulos A; White PJ; May LT
    Biochem Pharmacol; 2016 Oct; 117():46-56. PubMed ID: 27520486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multisite Model of Allosterism for the Adenosine A1 Receptor.
    Deganutti G; Barkan K; Ladds G; Reynolds CA
    J Chem Inf Model; 2021 Apr; 61(4):2001-2015. PubMed ID: 33779168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective effects of adenosine A1 and A3 receptor activation during hypoxia in isolated rat cardiac myocytes.
    Safran N; Shneyvays V; Balas N; Jacobson KA; Nawrath H; Shainberg A
    Mol Cell Biochem; 2001 Jan; 217(1-2):143-52. PubMed ID: 11269659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke.
    Liston TE; Hama A; Boltze J; Poe RB; Natsume T; Hayashi I; Takamatsu H; Korinek WS; Lechleiter JD
    Stroke; 2022 Jan; 53(1):238-248. PubMed ID: 34802248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist.
    Valant C; May LT; Aurelio L; Chuo CH; White PJ; Baltos JA; Sexton PM; Scammells PJ; Christopoulos A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(12):4614-9. PubMed ID: 24619092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic heart failure increases negative chronotropic effects of adenosine in canine sinoatrial cells via A1R stimulation and GIRK-mediated I
    Long VP; Bonilla IM; Baine S; Glynn P; Kumar S; Schober K; Mowrey K; Weiss R; Lee NY; Mohler PJ; Györke S; Hund TJ; Fedorov VV; Carnes CA
    Life Sci; 2020 Jan; 240():117068. PubMed ID: 31751583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.